Prognosis and monitoring of giant cell arteritis and associated complications

References

• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–1461.
   PubMed Web of Science ®Google Scholar
• Soriano A, Muratore F, Pipitone N, et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol. 2017;13:476–484.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234–245.
   PubMed Web of Science ®Google Scholar
• Broder MS, Sarsour K, Chang E, et al. Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. Semin Arthritis Rheum. 2016;46:246–252.
   PubMed Web of Science ®Google Scholar
• Chandran A, Udayakumar PD, Kermani TA, et al. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol. 2015;33:S-98–102.
   PubMed Web of Science ®Google Scholar
• Wilson JC, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Semin Arthritis Rheum. 2017;46:819–827.
   PubMed Web of Science ®Google Scholar
• Wilson JC, Sarsour K, Collinson N, et al. Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. Semin Arthritis Rheum. 2017;46:650–656.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Sreih AG, Cuthbertson D, et al. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018;57:322–328.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Dasgupta B. Current and emerging therapies in large-vessel vasculitis. Rheumatology (Oxford). 2017.
   PubMed Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921–1927.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–328.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283–292.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53:293–297.
   PubMed Web of Science ®Google Scholar
• Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42:309–315.
   PubMed Web of Science ®Google Scholar
• Saleh M, Turesson C, Englund M, et al. Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol. 2016;43:1559–1565.
   PubMed Web of Science ®Google Scholar
• Ji J, Dimitrijevic I, Sundquist J, et al. Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden. Scand J Rheumatol. 2017;46:484–489.
   PubMed Web of Science ®Google Scholar
• Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015;372:2428–2436.
   PubMed Web of Science ®Google Scholar
• Kale N, Eggenberger E. Diagnosis and management of giant cell arteritis: a review. Curr Opin Ophthalmol. 2010;21:417–422.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Haugeberg G, Lindland A, et al. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 2016;55:66–70.
   PubMed Web of Science ®Google Scholar
• Patil P, Williams M, Maw WW, et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33:S-103–6.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Leavitt JA, Fang C, et al. Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmology. 2016;123:1999–2003.
   PubMed Web of Science ®Google Scholar
• Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26–32.
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation. 2003;107:2428–2434.
   PubMed Web of Science ®Google Scholar
• Liozon E, Dalmay F, Lalloue F, et al. Risk factors for permanent visual loss in biopsy-proven giant cell arteritis: a study of 339 patients. J Rheumatol. 2016;43:1393–1399.
   PubMed Web of Science ®Google Scholar
• Mackie SL, Dasgupta B, Hordon L, et al. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. Rheumatology. 2011;50:2014–2022.
   PubMed Web of Science ®Google Scholar
• Yates M, MacGregor AJ, Robson J, et al. The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology (Oxford). 2017;56:524–528.
   PubMed Web of Science ®Google Scholar
• Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–317.
   PubMed Web of Science ®Google Scholar
• Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2014;54:463–470.
   PubMed Web of Science ®Google Scholar
• Schmidt WA, Moll A, Seifert A, et al. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47:1406–1408.
   PubMed Web of Science ®Google Scholar
• Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211–217.
   PubMed Web of Science ®Google Scholar
• Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550–555.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–630.
   PubMed Web of Science ®Google Scholar
• Chan CC, Paine M, O’Day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J Neuroophthalmol. 2005;25:14–17.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42:1213–1217.
   PubMed Web of Science ®Google Scholar
• Schonau V, Vogel K, Englbrecht M, et al. The value of (18)F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis. 2018;77:70–77.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72:1989–1994.
   PubMed Web of Science ®Google Scholar
• Naderi N, Mohammad AJ, Turesson C. Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution, and predictors. Scand J Rheumatol. 2017;46:215–221.
   PubMed Web of Science ®Google Scholar
• Agard C, Barrier JH, Dupas B, et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008;59:670–676.
   PubMed Web of Science ®Google Scholar
• Aschwanden M, Kesten F, Stern M, et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2 × 11 arterial regions. Ann Rheum Dis. 2010;69:1356–1359.
   PubMed Web of Science ®Google Scholar
• Blockmans D, Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Care Res. 2006;55:131–137.
   Web of Science ®Google Scholar
• Czihal M, Zanker S, Rademacher A, et al. Sonographic and clinical pattern of extracranial and cranial giant cell arteritis. Scand J Rheumatol. 2012;41:231–236.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Haugeberg G, Hetland H, et al. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res. 2014;66:113–119.
   PubMed Web of Science ®Google Scholar
• Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology. 2012;51:730–734.
   PubMed Web of Science ®Google Scholar
• Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71:1170–1176.
   PubMed Web of Science ®Google Scholar
• Prieto-Gonzalez S, Depetris M, Garcia-Martinez A, et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. Ann Rheum Dis. 2014;73:1388–1392.
   PubMed Web of Science ®Google Scholar
• Berthod PE, Aho-Glele S, Ornetti P, et al. CT analysis of the aorta in giant-cell arteritis: a case-control study. Eur Radiol. 2018.
   PubMedGoogle Scholar
• Grayson PC, Tomasson G, Cuthbertson D, et al. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol. 2012;39:303–309.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Liozon E, Lambert M, et al. Giant-cell arteritis: do we treat patients with large-vessel involvement differently? Am J Med. 2017;130:992–995.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594–1597.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018.
   Google Scholar
• Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121:e266–369.
   PubMed Web of Science ®Google Scholar
• Czihal M, Piller A, Schroettle A, et al. Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. J Vasc Surg. 2015;61:1285–1291.
   PubMed Web of Science ®Google Scholar
• Assie C, Janvresse A, Plissonnier D, et al. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore). 2011;90:40–51.
   PubMed Web of Science ®Google Scholar
• Czihal M, Piller A, Schroettle A, et al. Outcome of giant cell arteritis of the arm arteries managed with medical treatment alone: cross-sectional follow-up study. Rheumatology. 2013;52:282–286.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Matteson EL, Hunder GG, et al. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol. 2009;36:2277–2283.
   PubMed Web of Science ®Google Scholar
• Le Hello C, Levesque H, Jeanton M, et al. Lower limb giant cell arteritis and temporal arteritis: followup of 8 cases. J Rheumatol. 2001;28:1407–1412.
   PubMed Web of Science ®Google Scholar
• Tato F, Hoffmann U. Clinical presentation and vascular imaging in giant cell arteritis of the femoropopliteal and tibioperoneal arteries. Analysis of four cases. J Vasc Surg. 2006;44:176–182.
   PubMed Web of Science ®Google Scholar
• Czihal M, Tato F, Rademacher A, et al. Involvement of the femoropopliteal arteries in giant cell arteritis: clinical and color duplex sonography. J Rheumatol. 2012;39:314–321.
   PubMed Web of Science ®Google Scholar
• Schmidt WA, Natusch A, Moller DE, et al. Involvement of peripheral arteries in giant cell arteritis: a color Doppler sonography study. Clin Exp Rheumatol. 2002;20:309–318.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Warrington KJ. Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis. Curr Opin Rheumatol. 2011;23:38–42.
   PubMed Web of Science ®Google Scholar
• Samson M, Jacquin A, Audia S, et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry. 2015;86:216–221.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Liozon E, Lariviere D, et al. Giant cell arteritis-related stroke: a retrospective multicenter case-control study. J Rheumatol. 2017;44:297–303.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83:335–341.
   PubMed Web of Science ®Google Scholar
• Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis. 2015;74:129–135.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Arguis P, Prieto-Gonzalez S, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2014;73:1826–1832.
   PubMed Web of Science ®Google Scholar
• Mackie SL, Hensor EMA, Morgan AW, et al. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis. 2014;73:143–148.
   PubMed Web of Science ®Google Scholar
• Blockmans D, Coudyzer W, Vanderschueren S, et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology. 2008;47:1179–1184.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Liozon E, Lambert M, et al. 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients. Medicine (Baltimore). 2016;95:e3851.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Warrington KJ, Crowson CS, et al. Predictors of dissection in aortic aneurysms from giant cell arteritis. J Clin Rheumatol. 2016;22:184–187.
   PubMed Web of Science ®Google Scholar
• Kebed DT, Bois JP, Connolly HM, et al. Spectrum of aortic disease in the giant cell arteritis population. Am J Cardiol. 2018;121:501–508.
   PubMed Web of Science ®Google Scholar
• Espitia O, Neel A, Leux C, et al. Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with longterm followup. J Rheumatol. 2012;39:2157–2162.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res. 2010;62:835–841.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Boivin V, Pasturel-Michon U, et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol. 2001;19:171–176.
   PubMed Web of Science ®Google Scholar
• Martinez-Lado L, Calvino-Diaz C, Pineiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90:186–193.
   PubMed Web of Science ®Google Scholar
• Nesher G, Nesher R, Mates M, et al. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol. 2008;26:S30–4.
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703–708.
   PubMed Web of Science ®Google Scholar
• Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford). 2016;55:347–356.
   PubMed Web of Science ®Google Scholar
• Restuccia G, Boiardi L, Cavazza A, et al. Flares in biopsy-proven giant cell arteritis in Northern Italy: characteristics and predictors in a long-term follow-up study. Medicine (Baltimore). 2016;95:e3524.
   PubMed Web of Science ®Google Scholar
• Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93:194–201.
   PubMed Web of Science ®Google Scholar
• Liozon E, Roblot P, Paire D, et al. Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford). 2000;39:1089–1094.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041–1048.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis: a systematic review. Jama. 2016;315:2442–2458.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318–323.
   PubMed Web of Science ®Google Scholar
• Harris E, Tiganescu A, Tubeuf S, et al. The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. Curr Rheumatol Rep. 2015;17:513.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Smail A, Roche B, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study. Arthritis Rheumatol. 2016;68:1477–1482.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Englund M, Turesson C, et al. Rate of comorbidities in giant cell arteritis: a population-based study. J Rheumatol. 2017;44:84–90.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–1318.
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–114.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495–501.
   PubMed Web of Science ®Google Scholar
• Mahr A, Saba M, Kambouchner M, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65:826–828.
   PubMed Web of Science ®Google Scholar
• Exley AR, Bacon PA, Luqmani RA, et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol. 1998;37:57–63.
   PubMedGoogle Scholar
• Amiri N, De Vera M, Choi HK, et al. Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study. Rheumatology (Oxford). 2016;55:33–40.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Bhole VM, Amiri N, et al. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. Ann Rheum Dis. 2016;75:148–154.
   PubMed Web of Science ®Google Scholar
• Li L, Neogi T, Jick S. Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK clinical practice research datalink. Rheumatology (Oxford). 2017;56:753–762.
   PubMed Web of Science ®Google Scholar
• Lo Gullo A, Koster MJ, Crowson CS, et al. Venous thromboembolism and cerebrovascular events in patients with giant cell arteritis: a population-based retrospective cohort study. PLoS One. 2016;11:e0149579.
   PubMed Web of Science ®Google Scholar
• Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart (British Cardiac Society). 2016;102:383–389.
   PubMed Web of Science ®Google Scholar
• Robson JC, Kiran A, Maskell J, et al. Which patients with giant cell arteritis will develop cardiovascular or cerebrovascular disease? A clinical practice research datalink study. J Rheumatol. 2016;43:1085–1092.
   PubMed Web of Science ®Google Scholar
• Tomasson G, Peloquin C, Mohammad A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160:73–80.
   PubMed Web of Science ®Google Scholar
• Udayakumar PD, Chandran AK, Crowson CS, et al. Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study. Arthritis Care Res. 2015;67:396–402.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Koster MJ, Thongprayoon C, et al. Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis. Clin Rheumatol. 2016;35:2741–2747.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Koster MJ, Warrington KJ. Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2015;44:586–591.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Thongprayoon C, Kittanamongkolchai W, et al. Peripheral arterial disease in patients with giant cell arteritis: a meta-analysis. Int J Rheum Dis. 2016;19:819–825.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Wijarnpreecha K, Koster MJ, et al. Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2016;46:361–366.
   PubMed Web of Science ®Google Scholar
• Unizony S, Lu N, Tomasson G, et al. Temporal trends of venous thromboembolism risk before and after diagnosis of giant cell arteritis. Arthritis Rheumatol. 2017;69:176–184.
   PubMed Web of Science ®Google Scholar
• Dagan A, Mahroum N, Segal G, et al. The association between giant cell arteritis and ischemic heart disease: a population based cross-sectional study. Isr Med Assoc J. 2017;19:411–414.
   PubMed Web of Science ®Google Scholar
• Hill CL, Black RJ, Nossent JC, et al. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46:513–519.
   PubMed Web of Science ®Google Scholar